Related Experiment Video

Updated: May 13, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

New agents in the arsenal to fight castrate-resistant prostate cancer

Erin E Ezzell1, Kuang S Chang, Benjamin J George

  • 1Hematology/Oncology Department, San Antonio Military Medical Center, 3551 Roger Brooke Drive, Fort Sam Houston, TX, 78234, USA. Erin.ezzell@amedd.army.mil

Current Oncology Reports
|February 27, 2013
PubMed

Insights

New treatments for castrate-resistant prostate cancer (CRPC) have emerged since 2010. This review covers four key agents, offering new options with proven clinical benefits for CRPC patients.

Area of Science:

  • Oncology
  • Urology
  • Pharmacology

Background:

  • Treatment options for castrate-resistant prostate cancer (CRPC) were limited prior to 2010.
  • Recent advancements have led to the approval of four new agents for CRPC by the US Food and Drug Administration.

Purpose of the Study:

  • To review the development and evolution of four new CRPC agents.
  • To examine the mechanisms of action, adverse events, and future directions for these novel therapies.

Main Methods:

  • Review of scientific literature on enzalutamide, abiraterone, cabazitaxel, and sipuleucel-T.
  • Analysis of investigational data and clinical trial outcomes for each agent.

Main Results:

  • Four distinct agents targeting CRPC have been approved, offering diverse mechanisms of action.
  • These agents represent significant progress in managing CRPC and provide clinically validated benefits.

Conclusions:

  • The landscape of CRPC treatment has significantly improved with the introduction of novel therapeutic agents.
  • Further research and understanding of these agents will guide future treatment strategies for advanced prostate cancer.

More Related Videos

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

Renal Capsule Xenografting and Subcutaneous Pellet Implantation for the Evaluation of Prostate Carcinogenesis and Benign Prostatic Hyperplasia08:38

Renal Capsule Xenografting and Subcutaneous Pellet Implantation for the Evaluation of Prostate Carcinogenesis and Benign Prostatic Hyperplasia

Published on: August 28, 2013

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...